Agnosia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: AGN002 MIFTS: 61	Agnosia Categories: Eye diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Agnosia

MalaCards integrated aliases for Agnosia:

Name: Agnosia ¹² ⁵⁴ ⁵⁵ ⁴⁵ ¹⁵ ¹⁷ ⁷⁴

Primary Visual Agnosia ⁵⁴ ⁷⁴

Dyspraxia ¹² ⁵⁵

Apraxias ⁴⁵ ⁷⁴

Monomodal Visual Amnesia ⁵⁴

Dyspraxia Syndrome ¹²

Visual Amnesia ⁵⁴

Alexia ⁷⁴

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Mental diseases Eye diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Symptoms and signs involving speech and voice

Dyslexia and other symbolic dysfunctions, not elsewhere classified

Agnosia

Apraxia

External Ids:

Disease Ontology ¹² DOID:4090

MeSH ⁴⁵ D000377 D001072

NCIt ⁵¹ C84542

SNOMED-CT ⁶⁹ 42341009 68345001 6950007

ICD10 ³⁴ R48.1 R48.2

EFO ¹⁷ EFO_0007136

UMLS ⁷⁴ C0001816 C0002018 C0003635 more

Sources

Summaries for Agnosia

NIH Rare Diseases : ⁵⁴ Agnosia is characterized by an inability to recognize and identify objects and/or persons. Symptoms may vary, according to the area of the brain that is affected. It can be limited to one sensory modality such as vision or hearing; for example, a person may have difficulty in recognizing an object as a cup or identifying a sound as a cough. Agnosia can result from strokes, traumatic brain injury, dementia, a tumor, developmental disorders, overexposure to environmental toxins (e.g., carbon monoxide poisoning), or other neurological conditions. Visual agnosia may also occur in association with other underlying disorders. People with agnosia may retain their cognitive abilities in other areas. Treatment of primary agnosia is symptomatic and supportive; when it is caused by an underlying disorder, treatment of the disorder may reduce symptoms and help prevent further brain damage.

MalaCards based summary : Agnosia, also known as primary visual agnosia, is related to pain agnosia and withdrawal disorder, and has symptoms including seizures, fever and dyspnea. An important gene associated with Agnosia is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Flurbiprofen and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include brain, parietal lobe and eye, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : ¹² A communication disorder that is a loss of ability to recognize objects, persons, sounds, shapes, or smells while the specific sense is not defective nor is there any significant memory loss.

NINDS : ⁵⁵ Agnosia is a rare disorder characterized by an inability to recognize and identify objects or persons. People with agnosia may have difficulty recognizing the geometric features of an object or face or may be able to perceive the geometric features but not know what the object is used for or whether a face is familiar or not. Agnosia can be limited to one sensory modality such as vision or hearing. For example, a person may have difficulty in recognizing an object as a cup or identifying a sound as a cough. Agnosia can result from strokes, dementia, developmental disorders, or other neurological conditions. It typically results from damage to specific brain areas in the occipital or parietal lobes of the brain. People with agnosia may retain their cognitive abilities in other areas.

Wikipedia : ⁷⁷ Agnosia is the inability to process sensory information. Often there is a loss of ability to recognize... more...

Sources

Related Diseases for Agnosia

Diseases in the Agnosia family:

Form Agnosia

Diseases related to Agnosia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)

#	Related Disease	Score	Top Affiliating Genes
1	pain agnosia	31.0	CCK CNR1 LIPN NPFF OPRK1 OPRL1
2	withdrawal disorder	30.0	CNR1 OPRM1 PDYN POMC
3	ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia	12.7
4	ocular motor apraxia	12.6
5	auditory agnosia	12.6
6	visual agnosia	12.6
7	ataxia-oculomotor apraxia 3	12.6
8	ataxia-oculomotor apraxia 4	12.5
9	apperceptive agnosia	12.5
10	rolandic epilepsy, mental retardation, and speech dyspraxia, x-linked	12.5
11	tactile agnosia	12.5
12	verbal auditory agnosia	12.5
13	finger agnosia	12.5
14	developmental dyspraxia	12.4
15	integrative agnosia	12.4
16	form agnosia	12.4
17	social emotional agnosia	12.4
18	associative agnosia	12.4
19	topographical agnosia	12.4
20	mirror agnosia	12.3
21	visual verbal agnosia	12.3
22	semantic agnosia	12.3
23	gait apraxia	12.3
24	time agnosia	12.3
25	spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2	12.2
26	color agnosia	12.2
27	apraxia of eyelid opening	12.2
28	primary progressive apraxia of speech	12.2
29	rolandic epilepsy-speech dyspraxia syndrome	12.1
30	astereognosia	12.0
31	autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome	12.0
32	x-linked intellectual disability-ataxia-apraxia syndrome	12.0
33	epilepsy, focal, with speech disorder and with or without mental retardation	12.0
34	pilarowski-bjornsson syndrome	11.8
35	childhood apraxia of speech	11.7
36	autotopagnosia	11.6
37	poretti-boltshauser syndrome	11.5
38	birk-landau-perez syndrome	11.5
39	balint syndrome	11.5
40	developmental coordination disorder	11.5
41	cortical deafness	11.5
42	gerstmann syndrome	11.5
43	prosopagnosia	11.5
44	intellectual disability-developmental delay-contractures syndrome	11.5
45	galactosemia	11.4
46	ataxia-telangiectasia	11.4
47	apraxia	11.4
48	alexia	11.4
49	wieacker-wolff syndrome	11.4
50	alzheimer disease 3	11.3

Graphical network of the top 20 diseases related to Agnosia:

Sources

Symptoms & Phenotypes for Agnosia

UMLS symptoms related to Agnosia:

seizures, fever, dyspnea, edema, cachexia, vertigo, headache, clumsiness, abnormality of extrapyramidal motor function, torticollis, syncope, scanning speech, cyanosis, visual agnosia, icterus, signs and symptoms, signs and symptoms, digestive, other symbolic dysfunction, hot flushes, muscle rigidity, symptoms

MGI Mouse Phenotypes related to Agnosia:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.1	ADRA2C CNR1 OPRD1 OPRK1 OPRL1 OPRM1
2	homeostasis/metabolism	MP:0005376	10.07	ADRA2C CCK CNR1 LIPN OPRD1 OPRK1
3	integument	MP:0010771	9.93	CNR1 OPRD1 OPRK1 OPRL1 OPRM1 OXT
4	adipose tissue	MP:0005375	9.85	CNR1 OPRM1 OXT PDYN POMC TRPV1
5	nervous system	MP:0003631	9.7	ADRA2C CCK CNR1 OPRD1 OPRK1 OPRL1
6	no phenotypic analysis	MP:0003012	9.17	CCK CNR1 OPRD1 OPRM1 PDYN POMC

Sources

Drugs & Therapeutics for Agnosia

Drugs for Agnosia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Flurbiprofen

Approved, Investigational

Phase 4

5104-49-4

3394

Dexmedetomidine

Approved, Vet_approved

Phase 4,Not Applicable

113775-47-6

5311068 68602

Dezocine

Approved, Investigational

Phase 4

53648-55-8

3033053 40841

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1

3821

Nalbuphine

Approved

Phase 4

20594-83-6

5311304 5360630

Bupivacaine

Approved, Investigational

Phase 4,Not Applicable

38396-39-3, 2180-92-9

2474

Morphine

Approved, Investigational

Phase 4,Phase 2,Phase 3,Not Applicable

57-27-2

5288826

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Not Applicable

50-02-2

5743

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4,Not Applicable

1177-87-3

Ibuprofen

Approved

Phase 4,Not Applicable

15687-27-1

3672

Acetaminophen

Approved

Phase 4,Phase 2,Phase 3,Not Applicable

103-90-2

1983

Levobupivacaine

Approved, Investigational

Phase 4,Not Applicable

27262-47-1

92253

Lidocaine

Approved, Vet_approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

137-58-6

3676

Sufentanil

Approved, Investigational

Phase 4,Not Applicable

56030-54-7

41693

Ropivacaine

Approved

Phase 4,Phase 3,Not Applicable

84057-95-4

175805 71273

Naloxone

Approved, Vet_approved

Phase 4

465-65-6

5284596

Oxycodone

Approved, Illicit, Investigational

Phase 4

76-42-6

5284603

Gabapentin

Approved, Investigational

Phase 4

60142-96-3

3446

Clonidine

Approved

Phase 4

4205-90-7

2803

Tramadol

Approved, Investigational

Phase 4,Phase 3

27203-92-5

33741

Remifentanil

Approved

Phase 4,Phase 3,Not Applicable

132875-61-7

60815

Ketoprofen

Approved, Vet_approved

Phase 4

22071-15-4

3825

Nefopam

Approved, Investigational

Phase 4

13669-70-0

Propofol

Approved, Investigational, Vet_approved

Phase 4,Phase 3

2078-54-8

4943

Analgesics, Opioid

Phase 4,Phase 2,Phase 3,Not Applicable

Analgesics

Phase 4,Phase 2,Phase 3,Not Applicable

Adrenergic alpha-Agonists

Phase 4,Not Applicable

Adrenergic Agents

Phase 4,Not Applicable

Cyclooxygenase Inhibitors

Phase 4,Not Applicable

Adrenergic Agonists

Phase 4,Not Applicable

Central Nervous System Depressants

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Analgesics, Non-Narcotic

Phase 4,Phase 2,Phase 3,Not Applicable

Neurotransmitter Agents

Phase 4,Not Applicable

Anti-Inflammatory Agents

Phase 4,Not Applicable

Adrenergic alpha-2 Receptor Agonists

Phase 4,Not Applicable

Hypnotics and Sedatives

Phase 4,Phase 3,Not Applicable

Narcotics

Phase 4,Phase 2,Phase 3,Not Applicable

Anti-Inflammatory Agents, Non-Steroidal

Phase 4,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antirheumatic Agents

Phase 4,Not Applicable

Excitatory Amino Acid Antagonists

Phase 4,Not Applicable

Anesthetics

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Anesthetics, Dissociative

Phase 4

Excitatory Amino Acids

Phase 4,Not Applicable

Anesthetics, General

Phase 4,Phase 3,Not Applicable

Anesthetics, Intravenous

Phase 4,Phase 3,Not Applicable

Adjuvants, Anesthesia

Phase 4,Phase 3,Not Applicable

Anesthetics, Local

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Antipyretics

Phase 4,Phase 2,Phase 3,Not Applicable

BB 1101

Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 73)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Dexmedetomidine for Postoperative Intravenous Patient Controlled Analgesia	Unknown status	NCT03014713	Phase 4	Dezocine;Flubiprofen;Dexmedetomidine
2	Ketamine and Postoperative Analgesia in Children	Unknown status	NCT00200564	Phase 4	ketamine
3	Intrathecal Morphine Analgesia vs. Continuous Epidural Analgesia vs. Systemic Analgesia in Colorectal Surgery.	Completed	NCT03007121	Phase 4	Morphine intrathecal;Bupivacaine + Sufentanil epidural;Morphine intravenous
4	Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks	Completed	NCT02523235	Phase 4	ropivacaine 0.2%
5	The Combination Effect of Dexmedetomidine and Morphine in Postoperative Patient-Controlled Analgesia	Completed	NCT00800826	Phase 4	dexmedetomidine
6	Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia	Completed	NCT02516059	Phase 4	oxycodone/naloxone;Oxycodone;Placebo
7	Multimodal Analgesic Treatment Versus Traditional Morphine Analgesia After Cardiac Surgery	Completed	NCT01966172	Phase 4	Ibuprofen;Gabapentin;Morphine;Paracetamol
8	Postoperative Pain and SIRS After Preoperative Analgesia With Clonidine or Levobupivacaine	Completed	NCT00860899	Phase 4	clonidine, levobupivacaine
9	Continuous Infusion of Dexamethasone Plus Tramadol Adjunct to Morphine PCA After Abdominal Hysterectomy	Completed	NCT00564603	Phase 4	Dexamethasone Sodium Phosphate Injection
10	Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections	Recruiting	NCT03105193	Phase 4	IV Saline bolus and infusion;IP Saline bolus and infusion;IV lignocaine bolus and infusion;IP Lignocaine bolus and infusion
11	Dexmedetomidine Supplemented Analgesia and 2-Year Survival After Cancer Surgery	Recruiting	NCT03012971	Phase 4	Dexmedetomidine supplemented morphine analgesia;Morphine analgesia
12	Dexmedetomidine Supplemented Intravenous Analgesia in Elderly After Orthopedic Surgery	Recruiting	NCT03629262	Phase 4	Dexmedetomidine;Placebo
13	Dexmedetomidine Supplemented Analgesia and Incidence of Postoperative Delirium	Recruiting	NCT03012984	Phase 4	Dexmedetomidine supplemented morphine analgesia;Morphine analgesia
14	Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.	Terminated	NCT01882530	Phase 4	Paracetamol;Nefopam;Ketoprofen;Morphine
15	A Study Comparing Two Analgesia/Sedation Regimens, Remifentanil/Propofol Versus Sufentanil/Propofol In Mechanically Ventilated Intensive Care Patients Requiring Analgesia And Sedation.	Terminated	NCT00421720	Phase 4	Sufentanil;Remifentanil
16	A PhaseⅡ/ Ⅲ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia	Unknown status	NCT02811991	Phase 2, Phase 3	Paracetamol injection;Normal Saline injection;Morhpine PCA
17	Combination Analgesia for Neonatal Circumcision	Completed	NCT02990364	Phase 3	Sucrose;Lidocaine;EMLA Topical Product
18	Wound Infusion vs Spinal Morphine for Post-caesarean Analgesia	Completed	NCT02264821	Phase 3	ropivacaine infiltration;intrathecal morphine;placebo
19	Tramadol Versus Fentanyl for Post-Operative Analgesia in Newborn Infants	Completed	NCT00713726	Phase 3	FentanyL;Tramadol
20	Continuous Regional Analgesia After Total Knee Arthroplasty	Completed	NCT00337597	Phase 3
21	Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU)	Terminated	NCT00436345	Phase 3	Remifentanil;Propofol
22	Development of a New Method for Analgesia	Completed	NCT00791024	Phase 1, Phase 2	CRC-Pharma 001;lidocaine suspension
23	Impact of Preemptive Intravenous Ibuprofen on Intraoperative Analgesia in Third Molar Teeth	Unknown status	NCT03170726	Not Applicable	arveles;intrafen 800 mg
24	Perfusion Index and Labor Analgesia	Unknown status	NCT03107559
25	Protective Analgesia in Caesarean Section Using Intravenous Paracetamol	Unknown status	NCT03060265	Not Applicable	Paracetamol;PLACEBO
26	Dexamethasone Added to Levobupivacaine Improves Postoperative Analgesia	Unknown status	NCT01739270	Not Applicable
27	Effect of N-methyl D-aspartate (NMDA) Receptor Antagonist Dextromethorphan on Opiods Analgesia and Tolerance in Pediatric Intensive Care Unit Patients	Unknown status	NCT01553435	Not Applicable	Dextromethorphan;Placebo
28	Do Epidurals Placed at a Lower Level Improve Labor Analgesia?	Unknown status	NCT00954317	Not Applicable
29	Depodur vs Fentanyl Infusion for Post-C/S Analgesia	Unknown status	NCT00762554	Not Applicable	Depodur;Depodur;Fentanyl
30	Low Level Laser (LED) Use to Increase Dental Implant Stability and Post Operative Analgesia	Unknown status	NCT01097499	Not Applicable
31	Effect of Thoracic Epidural Analgesia for Thoracotomy on the Occurrence of AF	Unknown status	NCT01718717	Not Applicable
32	Dietary Supplement for the Prevention of Cognitive Decline in a Very Elderly Population.	Unknown status	NCT01817101	Not Applicable
33	Perception and Multisensory Integration in Neurological Patients Using fMRI	Unknown status	NCT01469858	Not Applicable
34	Orientation Agnosia: Clinical and Anatomical Study	Completed	NCT01304576	Not Applicable
35	Newborn Cortical Response to Pain and Non Pharmacological Analgesia	Completed	NCT03389789	Not Applicable
36	Comparison of Patient-Controlled Analgesia With Different Background Infusion	Completed	NCT03221491	Not Applicable
37	Epidural Morphine for Postoperative Analgesia After Total Knee Arthroplasty	Completed	NCT03203967	Not Applicable	Intravenous morphine analgesia
38	Individualized Analgesia on Respiratory Adverse Events After Adenotonsillectomy	Completed	NCT02990910	Not Applicable	personalized opioid analgesia
39	A Randomised Controlled Trial Comparing Single Shot Adductor Canal Block With Local Infiltration Analgesia for Postoperative Analgesia After Total Knee Arthroplasty	Completed	NCT02104934	Not Applicable
40	μ-opioid Receptor Polymorphism and Opioid Analgesia	Completed	NCT02099877		Fentanyl
41	The Effect of Oxytocin on Placebo Analgesia: an Experimental Study in Healthy Volunteers	Completed	NCT01886014	Not Applicable	Oxytocin
42	Labour Analgesia and Movement in Babies	Completed	NCT01280084
43	The Randomised Epidural Analgesia in Term Delivering Women Trial (TREAT)	Completed	NCT01261689	Not Applicable	Ropivacaine/ Sufentanil according to local hospital protocol
44	Effect of Timing on Efficacy of Morphine Analgesia After 2-chloroprocaine Anesthesia	Completed	NCT00487084	Not Applicable	Morphine-CP-saline (MCS);saline-2CP-morphine (SCM);saline-lidocaine-morphine (SLM)
45	Combined Implementation of Dural Puncture Epidural and Programmed Intermittent Epidural Bolus for Labor Analgesia	Completed	NCT03366935	Not Applicable
46	Individualized Timing of Analgesia and Effectiveness of Labor Analgesia	Completed	NCT02920489	Not Applicable	Individualized epidural analgesia;Routine epidural analgesia
47	Epidural Analgesia in Intensive Care Unit (APD-REA: Analgesie PeriDurale en REAnimation)	Completed	NCT01437358
48	Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study	Completed	NCT01220362	Not Applicable	Bupivacain 0.125%;Bupivacain 0.125%/Fentanyl 2mcg/ml
49	Surgical Stress Index as a Tool for Monitoring Analgesia and/or Sedation in Critically Ill Patients	Completed	NCT00789412
50	Telemedically Supported Analgesia in the Emergency Medical Service	Completed	NCT01644032	Not Applicable

Search NIH Clinical Center for Agnosia

Cochrane evidence based reviews: agnosia

Sources

Genetic Tests for Agnosia

Sources

Anatomical Context for Agnosia

MalaCards organs/tissues related to Agnosia:

⁴²

Brain, Parietal Lobe, Eye, Colon, Cortex, Temporal Lobe, Breast

Sources

Publications for Agnosia

Articles related to Agnosia:

(show top 50) (show all 442)

#	Title	Authors	Year
1	Evidence of taxonomy for Developmental Topographical Disorientation: Developmental Landmark Agnosia Case 1. ( 29192795 )	Piccardi L...Pizzamiglio MR	2019
2	Patient MW: transient visual hemi-agnosia. ( 30617908 )	Decramer T...Theys T	2019
3	Real-world size coding of solid objects, but not 2-D or 3-D images, in visual agnosia patients with bilateral ventral lesions. ( 30987739 )	Holler DE...Snow JC	2019
4	Late-onset Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes Presenting With Auditory Agnosia. ( 31045719 )	Smith K...Keegan BM	2019
5	Transient Dyschromatopsia, Static Form Agnosia, and Prosopagnosia Observed in a Patient with Anti-NMDA Receptor Encephalitis. ( 31061739 )	Hashimoto R...Kato H	2019
6	Impaired peripheral reaching and on-line corrections in patient DF: Optic ataxia with visual form agnosia. ( 28532578 )	Rossit S...McIntosh RD	2018
7	Relationship between somatosensory event-related potential N140 aberrations and hemispatial agnosia in patients with stroke: a preliminary study. ( 29076767 )	Ueno T...Yamada T	2018
8	Congenital prosopagnosia without object agnosia? A literature review. ( 29165034 )	Geskin J...Behrmann M	2018
9	The neuropsychological rehabilitation of visual agnosia and Balint's syndrome. ( 29366371 )	Heutink J...Cordes C	2018
10	Perceptual deficits of object identification: apperceptive agnosia. ( 29519462 )	Milner AD...Cavina-Pratesi C	2018
11	Verbal auditory agnosia in a patient with traumatic brain injury: A case report. ( 29538212 )	Kim JM...Park D	2018
12	Agnosia for bird calls. ( 29572063 )	Muhammed L...Warren JD	2018
13	Supramodal agnosia for oblique mirror orientation in patients with periventricular leukomalacia. ( 29655042 )	Castaldi E...Morrone MC	2018
14	Should developmental prosopagnosia, developmental body agnosia, and developmental object agnosia be considered independent neurodevelopmental conditions? ( 29658410 )	Gray KLH...Cook R	2018
15	Association vs dissociation and setting appropriate criteria for object agnosia. ( 29658418 )	Garrido L...DeGutis J	2018
16	Visual texture agnosia in dementia with Lewy bodies and Alzheimer's disease. ( 29673784 )	Oishi Y...Suzuki K	2018
17	The contribution of facial dynamics to subtle expression recognition in typical viewers and developmental visual agnosia. ( 29723598 )	Yitzhak N...Aviezer H	2018
18	Apraxia, Neglect, and Agnosia. ( 29851877 )	Coslett HB	2018
19	Agnosia Interferes With Daily Hygiene in Patients With Dementia. ( 29900188 )	Hamdy RC...Whalen K	2018
20	Neuromodulation of Right Auditory Cortex Selectively Increases Activation in Speech-Related Brain Areas in Brainstem Auditory Agnosia. ( 30239465 )	Bestelmeyer PEG...Rafal RD	2018
21	Functional connectivity and the failure to retrieve meaning from shape in visual object agnosia. ( 30591372 )	Ptak R...Lazeyras F	2018
22	Emotional quotient in frontotemporal dementia vs. Alzheimer's disease: the role of socioemotional agnosia. ( 27903133 )	Carr AR...Mendez MF	2017
23	Landmark Agnosia: Evaluating the Definition of Landmark-based Navigation Impairment. ( 28164221 )	van der Ham IJM...van den Berg E	2017
24	Pure Amorphagnosia without Tactile Object Agnosia. ( 28559827 )	Kubota S...Tsujihata M	2017
25	Stroke of the inferiomedial temporal lobe causing word agnosia. ( 28747411 )	Hassan H...Pattanshetti M	2017
26	Visual agnosia and focal brain injury. ( 28843416 )	Martinaud O	2017
27	The painter from Sinaloa: artistic analysis of a case of spatial agnosia and neglect of visual shapes. ( 29185377 )	Orjuela-Rojas JM...Leyva Townsend N	2017
28	Auditory agnosia caused by bilateral putamen haemorrhage. ( 29269367 )	Sugiura T...Torii T	2017
29	Auditory agnosia associated with bilateral putaminal hemorrhage: A case report of clinical course of recovery. ( 28740065 )	Tokida H...Kuriyama M	2017
30	Which visual functions depend on intermediate visual regions? Insights from a case of developmental visual form agnosia. ( 26209358 )	Gilaie-Dotan S	2016
31	Visual agnosia. ( 26358494 )	?lvarez R...Masjuan J	2016
32	Tactile Toe Agnosia and Percept of a "Missing Toe" in Healthy Humans. ( 26562866 )	Cicmil N...Stein JF	2016
33	Functional dissociation between action and perception of object shape in developmental visual object agnosia. ( 26827163 )	Freud E...Gilaie-Dotan S	2016
34	Agnosia for head tremor in essential tremor: prevalence and clinical correlates. ( 26877883 )	Eken HN...Louis ED	2016
35	Hurt but still alive: Residual activity in the parahippocampal cortex conditions the recognition of familiar places in a patient with topographic agnosia. ( 26909331 )	van Assche M...Assal F	2016
36	Enhancing diversity in academic neurology: From agnosia to action. ( 26972163 )	Hamilton RH	2016
37	What's in the name 'alexithymia'? A commentary on "Affective agnosia: Expansion of the alexithymia construct and a new opportunity to integrate and extend Freud's legacy.". ( 27235080 )	Taylor GJ...Parker JDA	2016
38	Poster 215 Gustatory Agnosia Following Herpes Simplex Virus Encephalitis: A Case Report. ( 27672976 )	Schultz S...Gater DR	2016
39	Impaired Velocity Processing Reveals an Agnosia for Motion in Depth. ( 27677897 )	Barendregt M...Rokers B	2016
40	Pearls & Oy-sters: Visual agnosia: An overlooked cortical sign. ( 27821572 )	Bergmans B...Bruffaerts R	2016
41	Auditory agnosia as a clinical symptom of childhood adrenoleukodystrophy. ( 25544384 )	Furushima W...Inagaki M	2015
42	Training-induced recovery of low-level vision followed by mid-level perceptual improvements in developmental object and face agnosia. ( 24698161 )	Lev M...Polat U	2015
43	The mitochondrial DNA 10197 G > A mutation causes MELAS/Leigh overlap syndrome presenting with acute auditory agnosia. ( 24708134 )	Leng Y...Wang Z	2015
44	Patient DF's visual brain in action: Visual feedforward control in visual form agnosia. ( 25199609 )	Whitwell RL...Goodale MA	2015
45	Visual processing of words in a patient with visual form agnosia: a behavioural and fMRI study. ( 25461705 )	Cavina-Pratesi C...Milner AD	2015
46	Auditory agnosia. ( 25726291 )	Slevc LR...Shell AR	2015
47	Real-time vision, tactile cues, and visual form agnosia: removing haptic feedback from a "natural" grasping task induces pantomime-like grasps. ( 25999834 )	Whitwell RL...Goodale MA	2015
48	Emergence delirium with transient associative agnosia and expressive aphasia reversed by flumazenil in a pediatric patient. ( 26035220 )	Drobish JK...Cook-Sather SD	2015
49	Affective agnosia: Expansion of the alexithymia construct and a new opportunity to integrate and extend Freud's legacy. ( 26054794 )	Lane RD...Smith R	2015
50	Pure word deafness with auditory object agnosia after bilateral lesion of the superior temporal sulcus. ( 26343343 )	Gutschalk A...Vogt-Schaden M	2015

Sources

Genes for Agnosia

Genes related to Agnosia (0 elite genes):

(show all 25)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	OPRM1	Opioid Receptor Mu 1	Protein Coding	19.76	DISEASES inferred ¹⁵
2	OPRL1	Opioid Related Nociceptin Receptor 1	Protein Coding	19.5	DISEASES inferred ¹⁵
3	OPRK1	Opioid Receptor Kappa 1	Protein Coding	19.42	DISEASES inferred ¹⁵
4	OPRD1	Opioid Receptor Delta 1	Protein Coding	19.39	DISEASES inferred ¹⁵
5	PDYN	Prodynorphin	Protein Coding	17.94	DISEASES inferred ¹⁵
6	POMC	Proopiomelanocortin	Protein Coding	17.86	DISEASES inferred ¹⁵
7	TAC1	Tachykinin Precursor 1	Protein Coding	17.64	DISEASES inferred ¹⁵
8	TRPV1	Transient Receptor Potential Cation Channel Subfamily V Member 1	Protein Coding	17.58	DISEASES inferred ¹⁵
9	PSENEN	Presenilin Enhancer, Gamma-Secretase Subunit	Protein Coding	17.53	DISEASES inferred ¹⁵
10	TCF21	Transcription Factor 21	Protein Coding	17.47	DISEASES inferred ¹⁵
11	CNR1	Cannabinoid Receptor 1	Protein Coding	17.42	DISEASES inferred ¹⁵
12	CCK	Cholecystokinin	Protein Coding	17.24	DISEASES inferred ¹⁵
13	LIPN	Lipase Family Member N	Protein Coding	17	DISEASES inferred ¹⁵
14	ADRA2C	Adrenoceptor Alpha 2C	Protein Coding	16.82	DISEASES inferred ¹⁵
15	OXT	Oxytocin/Neurophysin I Prepropeptide	Protein Coding	8.79	DISEASES inferred ¹⁵
16	PNOC	Prepronociceptin	Protein Coding	8.13	DISEASES inferred ¹⁵
17	NPFF	Neuropeptide FF-Amide Peptide Precursor	Protein Coding	7.76	DISEASES inferred ¹⁵
18	TRIM13	Tripartite Motif Containing 13	Protein Coding	7.57	DISEASES inferred ¹⁵
19	RPL34	Ribosomal Protein L34	Protein Coding	7.56	DISEASES inferred ¹⁵
20	SLC22A18	Solute Carrier Family 22 Member 18	Protein Coding	7.55	DISEASES inferred ¹⁵
21	FOXP2	Forkhead Box P2	Protein Coding	6.79	DISEASES inferred ¹⁵
22	ADRA2A	Adrenoceptor Alpha 2A	Protein Coding	6.78	DISEASES inferred ¹⁵
23	FAAH	Fatty Acid Amide Hydrolase	Protein Coding	6.77	DISEASES inferred ¹⁵
24	ADRA2B	Adrenoceptor Alpha 2B	Protein Coding	6.72	DISEASES inferred ¹⁵
25	ADRA1B	Adrenoceptor Alpha 1B	Protein Coding	6.71	DISEASES inferred ¹⁵

Sources

Variations for Agnosia

Sources

Expression for Agnosia

Search GEO for disease gene expression data for Agnosia.

Sources

Pathways for Agnosia

Pathways related to Agnosia according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Signaling by GPCR ⁶⁷ Show member pathways GPCR downstream signaling ⁶⁷ Signal Transduction ⁶⁷	13.5	ADRA2C CCK CNR1 NPFF OPRD1 OPRK1
2	Peptide ligand-binding receptors ⁶⁷ Show member pathways Class A/1 (Rhodopsin-like receptors) ⁶⁷ Defective AVP causes neurohypophyseal diabetes insipidus (NDI) ⁶⁷ Formyl peptide receptors bind formyl peptides and many other ligands ⁶⁷ G alpha (i) signalling events ⁶⁷ GPCR ligand binding ⁶⁷ GPCRs, Class A Rhodopsin-like ¹ Neuroactive ligand-receptor interaction ³⁸ Orexin and neuropeptides FF and QRFP bind to their respective receptors ⁶⁷ Peptide GPCRs ¹ Tachykinin receptors bind tachykinins ⁶⁷ Vasopressin-like receptors ⁶⁷	12.75	ADRA2C CCK CNR1 NPFF OPRD1 OPRK1
3	Neuroscience ⁴	12.24	CNR1 OPRM1 POMC PSENEN
4	ADP signalling through P2Y purinoceptor 12 ⁶⁷ Show member pathways Adrenaline,noradrenaline inhibits insulin secretion ⁶⁷ Beta-agonist/Beta-blocker Pathway, Pharmacodynamics ⁶² Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding ⁶⁷ G alpha (z) signalling events ⁶⁷ G-protein activation ⁶⁷ Signal transduction cAMP signaling ²³	12.12	ADRA2C OPRM1 PDYN POMC
5	Interleukin-4 and 13 signaling ⁶⁷	11.6	OPRD1 OPRM1 POMC
6	Syndecan-3-mediated signaling events ¹	10.49	POMC PSENEN
7	Cell-type Dependent Selectivity of CCK2R Signaling ¹	10.27	CCK CNR1

Sources

GO Terms for Agnosia

Cellular components related to Agnosia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	axon	GO:0030424	9.85	ADRA2C CCK CNR1 OPRM1 TAC1
2	neuronal cell body	GO:0043025	9.73	CCK OPRK1 PDYN PNOC TAC1 TRPV1
3	perikaryon	GO:0043204	9.67	CCK NPFF OPRK1 OPRM1
4	integral component of postsynaptic membrane	GO:0099055	9.61	ADRA2C OPRK1 OPRM1
5	dendrite	GO:0030425	9.5	CCK NPFF OPRK1 OPRM1 PDYN PNOC
6	integral component of presynaptic membrane	GO:0099056	9.46	CNR1 OPRD1 OPRK1 OPRM1
7	spine apparatus	GO:0097444	9.32	OPRD1 OPRM1
8	axon terminus	GO:0043679	9.1	ADRA2C NPFF OPRD1 OPRK1 PDYN PNOC
9	plasma membrane	GO:0005886	10.26	ADRA2C CNR1 OPRD1 OPRK1 OPRL1 OPRM1
10	integral component of plasma membrane	GO:0005887	10.01	ADRA2C CNR1 OPRD1 OPRK1 OPRL1 OPRM1

Biological processes related to Agnosia according to GeneCards Suite gene sharing:

(show all 37)

#	Name	GO ID	Score	Top Affiliating Genes
1	chemical synaptic transmission	GO:0007268	9.97	NPFF OPRK1 PDYN PNOC TAC1
2	positive regulation of cytosolic calcium ion concentration	GO:0007204	9.88	NPFF OXT TAC1 TRPV1
3	response to ethanol	GO:0045471	9.84	CNR1 OPRK1 OPRM1
4	female pregnancy	GO:0007565	9.83	ADRA2C OXT PNOC
5	memory	GO:0007613	9.81	CCK CNR1 OXT
6	excitatory postsynaptic potential	GO:0060079	9.8	NPFF OPRM1 TRPV1
7	sensory perception of pain	GO:0019233	9.8	CNR1 OPRK1 OPRL1 OPRM1 TAC1 TRPV1
8	G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	GO:0007187	9.79	CNR1 OPRD1 OPRM1
9	adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	GO:0007193	9.78	OPRD1 OPRK1 OPRL1 OPRM1
10	phospholipase C-activating G protein-coupled receptor signaling pathway	GO:0007200	9.77	OPRD1 OPRK1 OPRM1
11	response to morphine	GO:0043278	9.77	CNR1 NPFF OPRK1 OPRM1 TAC1
12	response to cocaine	GO:0042220	9.76	CNR1 OPRK1 OPRM1 OXT
13	negative regulation of blood pressure	GO:0045776	9.75	CNR1 OPRL1 OXT
14	sensory perception	GO:0007600	9.73	OPRK1 OPRL1 OPRM1 PNOC
15	opioid receptor signaling pathway	GO:0038003	9.71	OPRD1 OPRK1 OPRL1 OPRM1
16	positive regulation of blood pressure	GO:0045777	9.7	CNR1 NPFF OXT
17	maternal process involved in female pregnancy	GO:0060135	9.67	CNR1 NPFF
18	response to food	GO:0032094	9.67	OPRM1 OXT
19	response to pain	GO:0048265	9.67	TAC1 TRPV1
20	estrous cycle	GO:0044849	9.67	OPRK1 OPRL1 OPRM1
21	positive regulation of ossification	GO:0045778	9.65	OXT TAC1
22	positive regulation of renal sodium excretion	GO:0035815	9.65	OXT TAC1
23	maternal behavior	GO:0042711	9.65	OPRK1 OXT
24	negative regulation of heart rate	GO:0010459	9.64	NPFF TAC1
25	behavior	GO:0007610	9.63	OPRK1 OPRL1
26	negative regulation of appetite	GO:0032099	9.63	CCK NPFF
27	eating behavior	GO:0042755	9.63	CCK OPRD1 OPRK1 OPRL1 OPRM1 OXT
28	acute inflammatory response to antigenic stimulus	GO:0002438	9.62	NPFF OPRM1
29	positive regulation of sensory perception of pain	GO:1904058	9.61	CCK OPRL1
30	neuropeptide signaling pathway	GO:0007218	9.61	NPFF OPRD1 OPRK1 OPRL1 OPRM1 PDYN
31	negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	GO:0106072	9.59	OPRL1 OPRM1
32	adenylate cyclase-inhibiting opioid receptor signaling pathway	GO:0031635	9.56	OPRK1 OPRM1
33	positive regulation of gastric acid secretion	GO:0060454	9.55	OPRL1 TRPV1
34	regulation of sensory perception of pain	GO:0051930	9.23	ADRA2C CCK NPFF OPRD1 OPRK1 OPRL1
35	signal transduction	GO:0007165	10.21	ADRA2C CCK CNR1 OPRD1 OPRK1 OPRL1
36	G protein-coupled receptor signaling pathway	GO:0007186	10.07	ADRA2C CCK CNR1 NPFF OPRD1 OPRK1
37	regulation of signaling receptor activity	GO:0010469	10.01	CCK NPFF OXT PDYN PNOC POMC

Molecular functions related to Agnosia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	hormone activity	GO:0005179	9.54	CCK OXT POMC
2	neuropeptide hormone activity	GO:0005184	9.46	CCK NPFF OXT PNOC
3	receptor serine/threonine kinase binding	GO:0033612	9.32	OPRD1 OPRK1
4	opioid peptide activity	GO:0001515	9.26	PDYN PNOC
5	neuropeptide binding	GO:0042923	9.26	OPRD1 OPRK1 OPRL1 OPRM1
6	opioid receptor activity	GO:0004985	8.92	OPRD1 OPRK1 OPRL1 OPRM1

Sources

Sources for Agnosia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia